This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freeth, J. S. Articles by Clayton, P. E. Search for Related Content PubMed PubMed Citation Articles by Freeth, J. S. Articles by Clayton, P. E.

Human Skin Fibroblasts as a Model of Growth Hormone (GH) Action in GH Receptor-Positive Laron’s Syndrome

Endocrine Sciences Research Group, Department of Medicine, University of Manchester, Manchester, United Kingdom M13 9PT; the Departments of Clinical Biochemistry (R.M.A.) and Molecular Medicine (P.T.), Kings College School of Medicine and Dentistry, London, United Kingdom SE5 9PJ; and the Department of Medicine, Bristol Royal Infirmary (M.R.N.), Bristol, United Kingdom BS2 8HW

Address all correspondence and requests for reprints to: Dr. P. E. Clayton, Endocrine Sciences Research Group, Department of Medicine, University of Manchester, Stopford Building, Oxford Road, Manchester, United Kingdom M13 9PT. E-mail: peter.clayton{at}man.ac.uk

Congenital GH insensitivity (Laron’s syndrome, LS) is often associated with a dysfunctional GH receptor (GHR) causing complete insensitivity to GH and absent serum GH-binding protein (GHBP). However, a proportion of children with LS have normal GHBP levels. We have identified four girls from two families with this condition (height SD score, -3.4 to -6.8) and undertaken studies on 1) their GHR genes and 2) their GH responses in cultured skin fibroblasts to define the etiology of their GH insensitivities.

No GHR gene mutations were identified in one family. In the other family, the affected siblings, an unaffected brother, and the father were heterozygous for a point mutation within exon 6 (D152H). In addition, use of intron 9 haplotypes to determine linkage to the GHR gene implied inheritance of different maternal GHR alleles in the two affected girls of the latter family. It is unlikely, therefore, that the D152H mutation alone could account for the LS phenotype.

End points of GH action [DNA synthesis, insulin-like growth factor-binding protein-3 (IGFBP-3) messenger RNA (mRNA) and peptide production] in skin fibroblast cultures established from three of the LS subjects and four normal children were examined. Whereas normal fibroblasts incorporated [³H]thymidine dose dependently in response to 10–1000 ng/ml GH (increment at 1000 ng/ml, 77 ± 19%), LS fibroblasts failed to respond significantly above basal levels (P < 0.01). In normal fibroblasts, IGFBP-3 mRNA and peptide increased maximally at 48 h in response to 200 ng/ml GH, as determined by ribonuclease protection assay, Western ligand blotting, and RIA. In comparison, LS fibroblasts produced significantly less IGFBP-3 peptide than normal fibroblasts in response to GH, whereas IGFBP-3 mRNA failed to increase above basal levels.

These studies have shown that 1) cultured human skin fibroblasts can be used to define the end points of GH action; 2) fibroblast cultures from the LS children show absent or reduced responses to GH; and 3) GH insensitivity in these children does not appear to be caused exclusively by GHR mutations, but is probably due to dysfunctional GHR signalling. Such patients may prove particularly important to elucidation of the key events in GH signaling.

This article has been cited by other articles:

				S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF]

				C. M. Silva, M. T. Kloth, A. J. Whatmore, J. S. Freeth, N. Anderson, K. K. Laughlin, T. Huynh, A. J. Woodall, and P. E. Clayton GH and Epidermal Growth Factor Signaling in Normal and Laron Syndrome Fibroblasts Endocrinology, July 1, 2002; 143(7): 2610 - 2617. [Abstract] [Full Text] [PDF]

				D. J. Mantell, P. E. Owens, N. J. Bundred, E. B. Mawer, and A. E. Canfield 1{alpha},25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo Circ. Res., August 4, 2000; 87(3): 214 - 220. [Abstract] [Full Text] [PDF]

				P. E Clayton and V. Tillmann Advances in endocrinology Arch. Dis. Child., March 1, 1998; 78(3): 278 - 284. [Full Text]

				J. S. Freeth, C. M. Silva, A. J. Whatmore, and P. E. Clayton Activation of the Signal Transducers and Activators of Transcription Signaling Pathway by Growth Hormone (GH) in Skin Fibroblasts from Normal and GH Binding Protein-Positive Laron Syndrome Children Endocrinology, January 1, 1998; 139(1): 20 - 28. [Abstract] [Full Text] [PDF]